“…Gene editing techniques, acting as a potential therapeutic option, have been widely investigated in treatment of the nuclear genetic diseases over the past decade ( Sharma et al, 2015 ; Nelson et al, 2016 ; De Ravin et al, 2017 ; Zheng et al, 2022 ), with an increasing number of clinical trials ongoing ( Arabi et al, 2022 ). However, its implication in mitochondrial diseases caused by mtDNA mutations has been hampered by the lack of efficient tools to manipulate the mtDNA ( Silva-Pinheiro and Minczuk, 2022 ), with the exception that deleterious mtDNA copies could be cut and eliminated by Zinc finger-fused ( Minczuk et al, 2008 ; Gammage et al, 2014 ; Gammage et al, 2016a ; Gammage et al, 2016b ; Gammage et al, 2018b ) or TALE-fused fokI nuclease ( Bacman et al, 2013 ; Reddy et al, 2015 ; Bacman et al, 2018 ; Pereira et al, 2018 ; Yang et al, 2018 ), as well as the monomeric enzyme based on the TALE system ( Pereira et al, 2018 ).…”